Iranian Journal of Neurology 2017. 16(4):192-200.

Molecular changes in obese and depressive patients are similar to neurodegenerative disorders
Laleh Habibi, Abbas Tafakhori, Rasoul Hadiani, Maryam Maserat-Mashhadi, Zeinab Kafrash, Shahla Torabi, Mohammad Azhdarzadeh, Seyed Mohammad Akrami, Morteza Mahmoudi, Rasoul Dinarvand


Background: Neurodegenerative disorders (NDs) are categorized as multifactorial conditions with different molecular and environmental causes. Disturbance of important signaling pathways, such as energy metabolism and inflammation induced by environmental agents, is involved in the pathophysiology of NDs. It has been proposed that changes in the lifestyle and nutrition (metabolism) during mid-life could trigger and accumulate cellular and molecular damages resulting in NDs during aging.

Methods: In order to test the hypothesis, we investigated the expression level of two energy metabolism-related [forkhead box O1 (FOXO1) and forkhead box O3 (FOXO3A)] and two pro-inflammatory cytokines [interleukin 1β (IL-1β) and IL-6] genes, using quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). Furthermore, changes in the ionic concentration of three essential heavy metals [iron (Fe), copper (Cu), and zinc (Zn)] by atomic absorption spectroscopy in patients with NDs, depression, obesity, and diabetes type II, were evaluated and compared with the results of normal individuals.

Results: More than half of the participants in obesity, depression, and ND groups had significant up-regulation of FOXO1 and FOXO3A, down-regulation of IL-1β and IL-6, and higher levels of Fe and Cu in their blood. This pattern of gene expression was not repeated in diabetic patients.

Conclusion: It could be concluded that individuals affected with different levels of obesity and depression have increased risk of developing NDs later in life, probably through changes in energy metabolism, inflammatory pathways, and ionic concentrations.


Obesity; Depression; Neurodegeneration; Forkhead Box Protein; Heavy Metals; Lifestyle

Full Text:



Sheikh S, Safia, Haque E, Mir SS. Neurodegenerative diseases: Multifactorial conformational diseases and their therapeutic interventions. J Neurodegener Dis 2013; 2013: 563481.

Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 2010; 19(R1): R12-R20.

Nakamura T, Lipton SA. Cell death: Protein misfolding and neurodegenerative diseases. Apoptosis 2009; 14(4): 455-68.

Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 2010; 345(1-2): 91-104.

Melo A, Monteiro L, Lima RM, Oliveira DM, Cerqueira MD, El-Bacha RS. Oxidative stress in neurodegenerative diseases: Mechanisms and therapeutic perspectives. Oxid Med Cell Longev2011; 2011: 467180.

Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther 2012;342(3): 619-30.

Hroudova J, Singh N, Fisar Z.Mitochondrial dysfunctions in neurodegenerative diseases: Relevance to Alzheimer's disease. Biomed Res Int2014; 2014: 175062.

Blandini F, Braunewell KH, Manahan- Vaughan D, Orzi F, Sarti P. Neurodegeneration and energy metabolism: From chemistry to clinics. Cell Death Differ 2004; 11(4): 479-84.

Maiese K. FoxO proteins in the nervous system. Anal Cell Pathol (Amst) 2015;2015: 569392.

Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol 2014; 112: 24-49.

Amor S, Peferoen LA, Vogel DY, Breur M, van der V, Baker D, et al. Inflammation in neurodegenerative diseases--an update. Immunology 2014;142(2): 151-66.

Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B. Environmentalpollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci 2015; 9: 124.

Kozlowski H, Janicka-Klos A, Brasun J, Gaggelli E, Valensin D, Valensin G. Copper, iron, and zinc ions homeostasis and their role in neurodegenerative disorders (metal uptake, transport, distribution and regulation). Coordination Chemistry Reviews 2009; 253(21): 2665-85.

Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative diseases: An overview of environmental risk factors. Environ Health Perspect 2005; 113(9):1250-6.

ManafiRad A, Farzadfar F, Habibi L, Azhdarzadeh M, Aghaverdi H, Tehrani KH, et al. Is amyloid-beta an innocent bystander and marker in Alzheimer's disease? Is the liability of multivalent cation homeostasis and its influence on amyloid-beta function the real mechanism? J Alzheimers Dis 2014;42(1): 69-85.

Lavallard VJ, Meijer AJ, Codogno P, Gual P. Autophagy, signaling and obesity. Pharmacol Res 2012; 66(6): 513-25.

Muriach M, Flores-Bellver M, Romero FJ, Barcia JM. Diabetes and the brain: Oxidative stress, inflammation, and autophagy. Oxid Med Cell Longev 2014;2014: 102158.

Stuart MJ, Baune BT. Depression and type 2 diabetes: Inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neurosci Biobehav Rev2012; 36(1): 658-76.

Nguyen DM, El-Serag HB. The epidemiology of obesity. Gastroenterol Clin North Am 2010; 39(1): 1-7.

Cheng D. Prevalence, predisposition and prevention of type II diabetes. Nutr Metab (Lond ) 2005; 2: 29.

Hidaka BH. Depression as a disease of modernity: Explanations for increasing prevalence. J Affect Disord 2012; 140(3):205-14.

Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: Obtaining care for the growing burden of neurodegenerative conditions. Neurology 2013; 80(21): 1989-96.

Ashrafian H, Harling L, Darzi A, Athanasiou 41. Zemva J, Schilbach K, Stohr O, Moll L, Franko A, Krone W, et al. Central FoxO3a and FoxO6 expression is down- regulated in obesity induced diabetes but not in aging. Exp Clin Endocrinol Diabetes 2012; 120(6): 340-50.

Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004; 53(2): 474-81.

Wuwongse S, Chang RC, Law AC. The putative neurodegenerative links between depression and Alzheimer's disease. Prog Neurobiol 2010; 91(4): 362-75.

Caraci F, Copani A, Nicoletti F, Drago F.Depression and Alzheimer's disease: eurobiological links and common pharmacological targets. Eur J Pharmacol2010; 626(1): 64-71.

Shin HR, Kim H, Kim KI, Baek SH.Epigenetic and transcriptional regulation of autophagy. Autophagy 2016; 12(11):2248-9.

Xu P, Das M, Reilly J, Davis RJ. JNK regulates FoxO-dependent autophagy in neurons. Genes Dev 2011; 25(4): 310-22.

Zhou J, Liao W, Yang J, Ma K, Li X, Wang Y, et al. FOXO3 induces FOXO1- dependent autophagy by activating the AKT1 signaling pathway. Autophagy 2012; 8(12): 1712-23.

Wang S, Xia P, Huang G, Zhu P, Liu J, Ye B, et al. FoxO1-mediated autophagy is required for NK cell development and innate immunity. Nat Commun 2016; 7: 11023.

Sengupta A, Molkentin JD, Yutzey KE.FoxO transcription factors promote autophagy in cardiomyocytes. J Biol Chem 2009; 284(41): 28319-31.

Kousteni S. FoxO1, the transcriptional chief of staff of energy metabolism. Bone 2012; 50(2): 437-43.

Nakae J, Oki M, Cao Y. The FoxO transcription factors and metabolic regulation. FEBS Lett 2008; 582(1): 54-67.

Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress- dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303(5666):2011-5.

Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ, Jr., DiStefano PS, et al. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 2002; 296(5567): 530-4.

Warr MR, Binnewies M, Flach J, Reynaud D, Garg T, Malhotra R, et al. FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature 2013; 494(7437): 323-7.

Zhao Y, Yang J, Liao W, Liu X, Zhang H, Wang S, et al. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol 2010; 12(7): 665-75.

Samuel VT, Choi CS, Phillips TG, Romanelli AJ, Geisler JG, Bhanot S, et al. Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 2006; 55(7): 2042-50.

Relling DP, Esberg LB, Fang CX, Johnson WT, Murphy EJ, Carlson EC, et al. High- fat diet-induced juvenile obesity leads to cardiomyocyte dysfunction and upregulation of Foxo3a transcription factor independent of lipotoxicity and apoptosis. J Hypertens 2006; 24(3): 549-61.

Yang XF, Fang P, Meng S, Jan M, Xiong X, Yin Y, et al. The FOX transcription factors regulate vascular pathology, diabetes and Tregs. Front Biosci (Schol Ed) 2009; 1: 420-36.

Zemva J, Schilbach K, Stohr O, Moll L, Franko A, Krone W, et al. Central FoxO3a and FoxO6 expression is down- regulated in obesity induced diabetes but not in aging. Exp Clin Endocrinol Diabetes 2012; 120(6): 340-50.

Guidotti G, Calabrese F, Anacker C, Racagni G, Pariante CM, Riva MA. Glucocorticoid receptor and FKBP5 expression is altered following exposure to chronic stress: Modulation by antidepressant treatment. Neuropsychopharmacology 2013; 38(4):616-27.

Gregor MF, Hotamisligil GS.Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-45.

Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11(2): 98-107.

Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. Psychol Bull 2014;140(3): 774-815.

Ramesh G, MacLean AG, Philipp MT.Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm 2013; 2013: 480739.

Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006; 74: 443-77.

Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52(3): 812-7.

Kozlowski H, Luczkowski M, Remelli M, Valensin D. Copper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases). Coordination Chemistry Reviews 2012;256(19): 2129-41.

Thomas B, Gautam A, Prasad BR, Kumari S. Evaluation of micronutrient (zinc, copper and iron) levels in periodontitis patients with and without diabetes mellitus type 2: A biochemical study. Indian J Dent Res 2013; 24(4):468-73.

Costa CS, Rohden F, Hammes TO, Margis R, Bortolotto JW, Padoin AV, et al. Resveratrol upregulated SIRT1, FOXO1, and adiponectin and downregulated PPARgamma1-3 mRNA expression in human visceral adipocytes. Obes Surg 2011; 21(3): 356-61.

Qiu H, Wang F, Liu C, Xu X, Liu B.TEAD1-dependent expression of the FoxO3a gene in mouse skeletal muscle. BMC Mol Biol 2011; 12: 1.

Li J, Moran T, Swanson E, Julian C, Harris J, Bonen DK, et al. Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet 2004; 13(16):1715-25.

Oberbach A, Schlichting N, Bluher M, Kovacs P, Till H, Stolzenburg JU, et al.Palmitate induced IL-6 and MCP-1 expression in human bladder smooth muscle cells provides a link between diabetes and urinary tract infections. PLoS One 2010; 5(5): e10882.

Habibi L, Shokrgozar MA, Tabrizi M, Modarressi MH, Akrami SM. Mercury specifically induces LINE-1 activity in a human neuroblastoma cell line. Mutat Res Genet Toxicol Environ Mutagen 2014; 759: 9-20.

Habibi L, Ebtekar M, Jameie SB.Immune and nervous systems share molecular and functional similarities: Memory storage mechanism. Scand J Immunol 2009; 69(4): 291-301.

de la Monte SM, Longato L, Tong M, Wands JR. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs 2009; 10(10): 1049-60.

Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41(10):1241-8.

Stegenga ME, van der Crabben SN, Dessing MC, Pater JM, van den Pangaart PS, de Vos AF, et al. Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production and neutrophil function in humans. Diabet Med 2008;25(2): 157-64.

Allan SM. The role of pro- and antiinflammatory cytokines in neurodegeneration. Ann N Y Acad Sci 2000; 917: 84-93.

Young JJ, Bruno D, Pomara N. A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord 2014; 169: 15-20.

Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta- analysis of cytokines in major depression. Biol Psychiatry 2010; 67(5): 446-57.

Smith JA, Das A, Ray SK, Banik NL.Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 2012; 87(1): 10-20.

Jia JP, Meng R, Sun YX, Sun WJ, Ji XM, Jia LF. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients

with Alzheimer's disease and vascular dementia. Neurosci Lett 2005; 383(1-2):12-6.

Carlson NG, Wieggel WA, Chen J, Bacchi A, Rogers SW, Gahring LC. Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. J Immunol 1999;163(7): 3963-8.

Ali C, Nicole O, Docagne F, Lesne S, MacKenzie ET, Nouvelot A, et al. Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor mediated excitotoxicity in the brain. J Cereb Blood Flow Metab 2000; 20(6):956-66.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.